Funded Study: Treatment of Canine Insulinoma

University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory

Study Title: Combining PAC-1 with palladia for treatment of macroscopic canine insulinoma.

Funded Study: Funded study for canine patients with insulinoma.

Purpose of Study: The purpose of this study is to evaluate if combining oral PAC-1 and palladia will be an effective treatment for controlling the growth and spread of insulinoma in pet dogs.

Inclusion Criteria:

- Dogs must have a diagnosis of neuroendocrine cancerous growths by cytology, with a history of insulinoma confirmed by histopathology and presence of visible presumed insulinoma recurrence or regional/distant metastases on computed tomographic scan (CT).
- Dogs must have visible presumed insulinoma recurrence or regional/distant metastases on computed tomographic scan (CT).
- NO treatment with any previous chemotherapy, radiation, or immunotherapies.
- The patient must be in good overall condition and have no other serious illness.

Eligibility Diagnostics: Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed in their dog:

1) Diagnosis of insulinoma with histopathology or cytology, if not already documented
2) Screening blood work (CBC and chemistry), Insulin/glucose ratio, protein/creatinine ratio and urinalysis.
3) CT scan of the abdomen

Treatment: The canine patient will have whole blood and urine collected at various time points following initial clinical presentation, and have serial computed tomography scans under light sedation. Pet dogs will be treated with standardized palliative therapies including oral prednisone (0.25mg/kg by mouth once to twice daily) and oral investigation will include the use of oral PAC-1 to be given 2-4 hours prior to oral palladia treatment on Monday, Wednesday, and Friday schedule for the duration of therapy. On scheduled revisits, dogs will have their blood and urine analyzed, and have their abdominal cavity imaged using computed tomography. Pet dogs will be followed throughout the course of their natural disease progression following continuous treatment with standardized palliative therapy and oral PAC-1 for a maximum time duration of 1 year (6 months of therapy + 6 months of follow-up observation).

Compensation: This is a partially funded study upon patient eligibility and enrollment. Prior to confirmed enrollment, pet owners will be responsible for all costs associated with enrollment criteria. Once the patient has been enrolled into the clinical trial owners will be responsible for exam fees, blood
work and prednisone changes. Once the patient is enrolled the trial will pay for recheck CT scans, insulin/glucose ratio, Palladia and PAC-1.

**Contact Information:** Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information.

Referring veterinarian and client calls are welcome.